Three Emerging New Drugs for NSCLC-Pemetrexed, Bortezomib, and Cetuximab

Three Emerging New Drugs for NSCLC-Pemetrexed, Bortezomib, and Cetuximab Sarita Dubey, Joan H. Schiller Oncologist 2005; 10: 282-291 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in lung cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the targets of new biologic anticancer drugs. Interpret pharmacodynamic characteristics of drugs and apply this information in clinical use. Identify approved indications for the use of these new drugs. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Apr. 8, 2005 Most Recent Review: Apr. 8, 2005* Most Recent Update: Apr. 8, 2005 Date Credit Expires: Apr. 12, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.